Cincera Therapeutics is a privately held biotechnology company based in Adelaide and Melbourne, Australia. We are developing a new class of orally bioavailable small molecules designed to treat highly prevalent inflammatory and fibrotic diseases, including chronic kidney disease, fibrotic liver conditions, metabolic-associated steatohepatitis (MASH), lung fibrosis and systemic sclerosis.